Cas No.: | 146478-72-0 |
Chemical Name: | 2-Pentenamide,4-(acetyloxy)-N-[(2R,3R,5S,6S)-6-[(2E,4E)-5-[(3R,4R,5R,7S)-4,7-dihydroxy-7-methyl-1,6-dioxaspiro[2.5]oct-5-yl]-3-methyl-2,4-pentadien-1-yl]tetrahydro-2,5-dimethyl-2H-pyran-3-yl]-,(2Z,4S)- |
SMILES: | CC(=O)O[C@@H](C)\C=C\C(=O)NC1[C@@H](C)O[C@@H](C/C=C(\C)/C=C/[C@@H]2[C@@H](O)C3(C[C@](O)(C)O2)OC3)[C@@H](C)C1 |
Formula: | C27H41NO8 |
M.Wt: | 507.61634 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | FR901464 is a potent spliceosome inhibitor with prominent anti-tumor and anti-cancer effects[1]. |
In Vitro: | FR901464 (10-20 ng/ml; 6-24 hours) inhibits the growth of murine solid tumors, Colon 38 carcinoma and Meth A fibrosarcoma. FR901464 induces characteristic G1 and G2/M phase arrest in the cell cycle and internucleosomal degradation of genomic DNA with the same kinetics as activation of SV40 promoter-dependent cellular transcription in M-8 tumor cells[1]. FR901464 (1-10 ng/ml; 16 hours) suppresses the transcription of some inducible endogenous genes but not house keeping genes in M-8 cells[1]. FR901464 exhibits potent anticancer activity. It shows enhancement of activity of a promoter of the SV40 DNA tumor virus at 10 nM concentration in M-8 cells[1]. |
References: | [1]. H Nakajima, et al. New antitumor substances, FR901463, FR901464 and FR901465. II. Activities against experimental tumors in mice and mechanism of action. J Antibiot (Tokyo). 1996 Dec;49(12):1204-11. [2]. Arun K Ghosh, et al. Enantioselective total syntheses of FR901464 and spliceostatin A and evaluation of splicing activity of key derivatives. J Org Chem. 2014 Jun 20;79(12):5697-709. |